ArticleFrontiers in bioengineering and biotechnology2026
Neutrophil membrane biomimetic nanoparticles encapsulating kartogenin promote articular cartilage regeneration.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Articular cartilage defect (ACD) is a refractory disease in sports medicine with poor self-healing ability, mainly due to inflammatory infiltration and insufficient chondrogenic differentiation of mesenchymal stem cells (MSCs). Conventional drug delivery systems suffer from poor absorption, rapid immune clearance and low targeting efficiency. Neutrophil membrane biomimetic nanoparticles hold great potential for targeted anti-inflammation and sustained drug delivery, while kartogenin (KGN) is a potent chondrogenic inducer. This study aimed to develop a neutrophil membrane-camouflaged KGN-loaded PLGA nanoparticle (KGN-NNPs) for ACD repair. Methods: KGN-NNPs were fabricated by wrapping neutrophil membranes onto KGN-loaded PLGA nanoparticles. Physicochemical properties were characterized by TEM, DLS, zeta potential, WB and drug release assays. Results: KGN-NNPs exhibited uniform spherical morphology with typical core-shell structure, stable size and zeta potential, and retained neutrophil membrane markers (TNF-α R, CD11b). Sustained KGN release over 30 days and pH-responsive release behavior were observed. KGN-NNPs showed excellent biocompatibility without cytotoxicity to MSCs. Discussion: Neutrophil membrane-camouflaged KGN-NNPs possess good biocompatibility, targeted anti-inflammatory activity and strong chondrogenic induction ability. This biomimetic nanodrug delivery system significantly promotes articular cartilage regeneration in rat ACD model, providing a novel and promising strategy for the treatment of ACD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.